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Abstract
Background
The growing number of identified genetic disease risk variants across dog breeds chal-
lenges the current state-of-the-art of population screening, veterinary molecular diagnos-
tics, and genetic counseling. Multiplex screening of such variants is now technologically
feasible, but its practical potential as a supportive tool for canine breeding, disease diagnos-
tics, pet care, and genetics research is still unexplored.
Results
To demonstrate the utility of comprehensive genetic panel screening, we tested nearly
7000 dogs representing around 230 breeds for 93 disease-associated variants using a cus-
tom-designed genotyping microarray (the MyDogDNA1 panel test). In addition to known
breed disease-associated mutations, we discovered 15 risk variants in a total of 34 breeds
in which their presence was previously undocumented. We followed up on seven of these
genetic findings to demonstrate their clinical relevance. We report additional breeds harbor-
ing variants causing factor VII deficiency, hyperuricosuria, lens luxation, von Willebrand’s
disease, multifocal retinopathy, multidrug resistance, and rod-cone dysplasia. Moreover,
we provide plausible molecular explanations for chondrodysplasia in the Chinook, cerebel-
lar ataxia in the Norrbottenspitz, and familiar nephropathy in the Welsh Springer Spaniel.
Conclusions
These practical examples illustrate how genetic panel screening represents a comprehen-
sive, efficient and powerful diagnostic and research discovery tool with a range of
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known disease alleles are more widespread across different breeds than previously recog-
nized. However, careful follow up studies of any unexpected discoveries are essential to
establish genotype-phenotype correlations, as is readiness to provide genetic counseling
on their implications for the dog and its breed.
Introduction
Novel mutations that underlie canine Mendelian disorders and traits are described at an accel-
erating pace, with 199 such variants currently described in the OMIA database [1]. Accord-
ingly, the number of hereditary diseases and genetic predispositions that a dog could
potentially be tested for is steadily increasing. For some breeds, up to ten breed-relevant DNA
tests are commercially available through different laboratories [2,3], posing a burden on dog
owners, breeders, and clinicians seeking information and pursuing comprehensive health
screening. Therefore, there is a need for accurate and comprehensive, cost-effective and easy
to use DNA screening solutions that provide breeders with results for several breed relevant
disorders with one sampling, analysis and reporting effort. Furthermore, such screening holds
great potential to serve as a discovery and diagnostic tool for researchers and veterinary
clinicians.
Several canine genetic disorders such as progressive retinal atrophies (PRAs; [4]), pyruvate
kinase deficiency [5], cystinurias [6] and spinocerebellar ataxias [7,8] are genetically heteroge-
neous, which means that multiple simultaneous genetic tests of variants in the same gene, or in
different genes, are needed to understand their background across and within pure breeds. It is
also nearly impossible to know in advance which DNA tests apply to a mixed breed dog.
Genetic panel screening solutions that facilitate comprehensive molecular diagnostics and help
exclude known disease-causing mutations are therefore expected to support pet health care
and research. Testing for other mutations, besides the known breed-relevant ones, also has the
potential to advance knowledge on breed prevalence of disease-linked variants in dogs. Initial
research discovery studies are often limited to one or a few breeds, leaving the true breed and
geographic distribution of a new disease-associated variant incompletely explored. Although
many mutations are considered breed specific [3], others such as the ones underlying degenera-
tive myelopathy (DM; [9]), hyperuricosuria (HUU; [10]) or factor VII (FVII) deficiency
[11,12] are thought to be ancient in their origins and therefore potentially widespread across
breeds. Shared breed ancestry is also reflected in the disease heritage of breed groups, with
examples including primary lens luxation (PLL; [13]) in the terrier breed group, and collie eye
anomaly (CEA; [14]) in collie-like herding breeds. Inadvertent or planned crossbreeding may
further complicate the distribution pattern of disease-causing variants.
We report here on the experience gained by an initial DNA panel screening feasibility evalu-
ation, testing for 93 variants underlying canine inherited disorders in nearly 7000 dogs repre-
senting more than 230 breeds. Our findings illustrate the power of such a comprehensive
genetic approach as a diagnostic platform and research discovery tool providing insights into
the distribution of disease alleles and inherited disorders across canine breeds. We further
demonstrate the clinical presentation and relevance of several of the novel discoveries for the
newly affected breeds. More broadly, our study highlights general issues related to high fidelity
multiplex testing, such as the need for careful genetic and clinicopathological follow up of
unexpected findings, maintenance of close ties with the research and dog community, and
appropriate genetic counseling.
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Materials and Methods
Animals and samples
All canine buccal swab or EDTA blood samples used for multiplex screening (N = 6788) were
originally submitted for commercial DNA testing at Genoscoper Laboratories (Genoscoper
Laboratories Oy, Helsinki, Finland) during 2013 to 2015. The majority of the study sample
consisted of Finnish dogs (69.5%), while samples from Russia (5.5%), the Netherlands (4.8%),
Germany (3.5%), the United States (2.7%), Great Britain (2.0%), France (1.9%) and Norway
(1.0%) represented other major subgroups. There were 233 different dog breeds represented
among the studied dogs, with 156 breeds accounted for with5 individuals (S1 Table). The
majority of the examined dogs (N = 4668; 68.8%) represented breeds with at least one prior
known breed-relevant DNA test included among the tested genetic variants. The breed of a
dog was reported by its owner with accompanying registration information confirming the dog
as being registered under Fédération Cynologique Internationale (FCI) or American Kennel
Club (AKC)- standards. This study was ethically approved by the Animal Ethics Committee of
the State Provincial Office of Southern Finland, Hämeenlinna, Finland (permit number:
ESAVI/6054/04.10.03/2012). All dog owners provided written consent for the use of their dog’s
DNA sample for research purposes.
Follow up samples of 233 Brazilian Terriers genotyped for the canine multifocal retinopathy
(cmr1) variant [15] only, and 41 Norrbottenspitzes genotyped for the Finnish Hound cerebellar
ataxia variant [16] only, were selected from the biobank of the canine genetics research group
at the University of Helsinki.
Multiplex panel design and validation
A custom genotyping microarray for selected canine disease-associated variants (S2 Table) was
developed based the robust and widely utilized Illumina Infinium HD Ultra platform (Illu-
mina, Inc., San Diego, CA, USA), and validated as the MyDogDNA1 test through Genoscoper
Laboratories Oy, Helsinki, Finland [17]. In brief, a comprehensive literature and online data-
base review [1,2] was first performed to identify and compile template sequence information
on target mutations underlying canine inherited disorders. Second, genotyping assays were
designed according to the manufacturer’s guidelines (Illumina, Inc.) to directly target known
point mutations, insertions and deletions. Each disease marker was replicated three times in
the array design. Finally, the accuracy and reproducibility of the panel test results was validated
with a set of experiments [17] addressing source sample type, internal replicate concordance,
test-retest reproducibility, and with evaluation by an independent DNA testing laboratory
(Antagene, France) submitting a selection of samples with known disease genotypes for blind
testing. Specific disease assays were validated by 1) genotyping of samples with genotypes
known a priori; 2) sequencing validation of identified disease genotypes a posteriori; 3) syn-
thetic oligonucleotides for rare conditions where no control samples were available.
Genotyping
Microarray analyses were carried out following manufacturer-recommended standard proto-
cols (Illumina, Inc., San Diego, CA, USA). All genotype data from samples with call rates below
95% of the analyzed markers was discarded to ensure high quality data, and all genotype calls
were manually evaluated.
All mutant allele findings in unexpected breeds were further confirmed by standard capillary
sequencing on an ABI3730xl DNA Analyzer instrument (Thermo Fisher Scientific, Inc., Wal-
tham, MA, USA) at the Sequencing Unit of the Finnish Institute of Molecular Medicine (FIMM).
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Sequencing primers for each investigated disease variant are listed in S3 Table. PCR reactions
were performed on ~20 ng of genomic DNA using Amplitaq Gold Master Mix (Applied Biosys-
tems, Waltham, MA, USA) with reactions initiated at 95°C for 5 min, followed by 34 cycles of
30 s at 95°C, 30 s at 64°C and 45 s at 72°C, and finally 10 min at 72°C. Pre-sequencing PCR prod-
uct clean-up was performed enzymatically using Exonuclease I (Exo1) and FastAP™ Thermosen-
sitive Alkaline Phosphatase (Thermo Fisher Scientific) according to the manufacturer’s protocol.
Additional separate genotyping for cmr1 in Brazilian Terriers took place using KASP genotyping
chemistry according to the manufacturer’s assay design (LGC Ltd., Middlesex, UK). Additional
separate genotyping for Finnish Hound cerebellar ataxia in the Norrbottenspitz was carried out
on a LightCycler 480 II instrument (Roche Diagnostics, Basel, Switzerland) using standard probe
hydrolysis detection chemistry with LC480 Probe Master Mix (Roche Diagnostics), and the fol-
lowing primers: 5’-CGTAGACTACGAGACTGCATTTATTCA-3’ (forward) and 5’-GATTA
AACATAGCTTGTGCACTGTGT-3’ (reverse); and probes: 5’-TGCTGCTCAGATGCTA-3’
(VIC) and 5’-TGCTGCTCAGGTGCTA-3’ (FAM).
Coagulation factor VII deficiency measurements
We collected citrated blood samples for coagulation analysis from a seven-year-old Welsh
Springer Spaniel female and her litter of six dogs, approximately two and a half years old at the
time of this study. The carrier female and her litter represented all genotypes (Nnormal = 1,
Ncarrier = 3, Naffected = 3) of a variant (F7 c. c.407G>A) predisposing to factor VII deficiency.
Routine coagulation screening tests carried out included measurement of prothrombin and
partial thromboplastin times (Movet Oy, Kuopio, Finland) as well as specific coagulation factor
activity analyses using factor deficient plasma as previously described [11].
Urine uric acid measurements
We evaluated manifestation of hyperuricosuria in fourteen Lagotto Romagnolo dogs represent-
ing all genotypes (Nnormal = 7, Ncarrier = 3, Naffected = 4) of a predisposing variant (SLC2A9
c.616G>T). The sample consisted of eight females and six males with a median age of one year
and one month at the time of the study (range ten months to seven years). Hyperuricosuria
was evaluated based on a previously described urine test [18], evaluating urine uric acid: creati-
nine concentration ratios. Fresh midstream catch urine samples were used for the determina-
tion. Uric acid was analyzed by an enzymatic method, and creatinine by a kinetic picric acid
method, using the reagents and adaptations of an automatic chemistry analyzer (Konelab 30i,
Thermo Fisher Scientific Oy, Vantaa, Finland).
Ophthalmology examinations
Ophthalmology examinations in Brazilian Terriers were performed by an ECVO (European
College of Veterinary Ophthalmologists) panelist or an ECVO diplomate. The examinations
included ophthalmoscopy, biomicroscopy and funduscopy, using tropicamide as the mydriatic.
An Optical Coherence Tomography (OCT) examination of one dog homozygous for the cmr1
mutation (BEST1 c.73C>T) was carried out at the HUS Eye and Ear Hospital (Helsinki, Fin-
land) using an OCT Plus SPECTRALIS device (Heidelberg Engineering GmbH, Heidelberg,
Germany). No mydriatic was used for the OCT examination.
Statistical and pedigree analyses
The statistical significance of observed differences in phenotype values between groups of dogs
was evaluated by standard unpaired t-tests and one-way analysis of variance (ANOVA).
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Pedigrees were drawn using GenoPro1 genealogy software [19], based on information
retrieved from the Finnish Kennel Club registry database [20].
Results
Microarray-based panel testing yields high fidelity results
We developed a custom-designed Illumina Infinium technology-based bead chip SNP geno-
typing microarray to screen dogs for 93 different genetic variants underlying a wide variety of
canine hereditary disorders and genetic predispositions (S2 Table). The performance of the
microarray was extensively validated as also described elsewhere [17]. Blood and buccal swab
samples performed equally well on the array (median marker call rates of 98.1% vs 98.2%,
respectively). Internal replicate and test-retest (reproducibility) concordances were 99.8%.
Only markers reaching 100% sensitivity and specificity upon testing with control genotypes, or
validated by an experiment with a synthetic control oligonucleotide, were considered for
reporting.
High overall carrier frequency of known mutations across breeds
For this study, we screened samples from 6788 dogs representing 233 breeds between 2013 and
2015. Mutant alleles of well-known hereditary disease traits were encountered in breeds as
expected based on current literature and database information. Carrier frequencies for known
breed-relevant disorders are listed in S1 Table for breeds represented by at least 30 dogs. Based
on the examined set of 93 disease variants, we observed that 17.8% (N = 1208) of the tested
dogs carried at least one of the tested variants, while 2.5% (N = 170) were genetically affected
for a disease condition. The maximum number of disorders carried by any individual dog was
three (observed in three dogs). Two disorder variants were carried by 1.0% (N = 66), and one
disorder variant by 16.8% (N = 1139) of the tested dogs.
The genetic panel screening approach revealed 15 known disease-linked variants in an addi-
tional 34 breeds in which they have not previously been documented in the peer-reviewed liter-
ature (Table 1). Each mutant allele finding in an additional breed was confirmed by a second
genetic technology, Sanger sequencing. After confirming the genetic presence of a mutation in
an additional breed, it is crucial to establish a genotype-phenotype correlation by exploring
whether the risk variant phenotypically manifests on a different genetic background. In this
study, clinical validation was initiated with owner interviews regarding clinical manifestations,
and where possible, continued by recruitment of genetically affected dogs for relevant clinico-
pathological examinations as described in the following sections.
Factor VII (FVII) deficiency is genetically widespread across breeds
Factor VII deficiency is a recessively inherited mild coagulopathy that may typically go
completely unnoticed until revealed by routine coagulation screening tests or episodes of exces-
sive bleeding due to trauma or surgery [11,12]. An F7missense mutation underlying canine
FVII deficiency was originally characterized in research colonies of Beagles, but later also
found in pet Beagles [11], Alaskan Klee Kais [12], and Scottish Deerhounds (U. Giger, unpub-
lished). We report here ten additional breeds of varying ancestry in which the presence of the
FVII deficiency-associated variant (F7 c.407G>A) had not been previously reported (Table 1).
In an effort to investigate whether the presence of the mutant allele also leads to a bleeding ten-
dency in these additional breeds, we evaluated in vitro the coagulation in heterozygous and
homozygous Welsh Springer Spaniels, and in a homozygous Finnish Hound. The three homo-
zygous mutant Welsh Springer Spaniels dogs recruited for this study had no prior history of
Comprehensive Screening for Hereditary Disorders in Dogs
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Table 1. Summary of disease variant findings in additional breeds.
Disorder Gene and mutation Previously reported
breeds
Additional breed(s) with N observed carriers
Catalase Deﬁciency CAT c.979G>A (p.Ala327Thr) Beagle American Foxhound: 1/1 (100%)
Chondrodysplasia (Dwarﬁsm) ITGA10 c.2083C>T (p.Arg695*) • Norwegian Elkhound,
grey
• Karelian Bear Dog
Chinook: 5/47 (10.6%)
Craniomandibular Osteopathy
(CMO)
SLC37A2 c.1332C>T (p.
Asp444Asp)
• Cairn Terrier
• Scottish Terrier
•West HighlandWhite
Terrier
• Australian Shepherd: 1/140 (0.7%)
• Lancashire Heeler: 1/40 (2.5%)
Factor VII (FVII) Deﬁciency F7 c.407G>A (p.Gly136Glu) • Alaskan Klee Kai
• Airedale Terrier
• Beagle
•Giant Schnauzer
• Scottish Deerhound
• American Foxhound: 1/1 (100%)
• Finnish Hound: 54/237 (22.8%)
• GermanWirehaired Pointer: 1/3 (33.3%)
• Irish Water Spaniel: 1/3 (33.3%)
• Japanese Spitz: 1/6 (16.7%)
•Miniature Schnauzer: 1/7 (14.3%)
• Papillon/Phalene: 5/41 (12.2%)
• Sealyham Terrier: 1/1 (100%)
•Welsh Springer Spaniel: 18/76 (23.7%)
Familial Nephropathy (FN) COL4A4 c.115A>T (p.Lys40*) • American Cocker
Spaniel
• English Cocker
Spaniel
Welsh Springer Spaniel: 10/76 (13.2%)
Hyperuricosuria (HUU) SLC2A9 c.616G>T (p.
Cys188Phe)
• Black Russian Terrier
• Dalmatian
• English Bulldog
• >10 other breeds
• Danish-Swedish Farmdog: 13/168 (7.7%)
• German Hunting Terrier: 3/22 (13.6%)
• Kromfohrländer: 1/160 (0.6%)
• Lagotto Romagnolo: 52/637 (8.2%)
• Spaniel de Pont-Audemer: 1/4 (25%)
• Swedish Vallhund: 3/71 (4.2%)
Multi-drug resistance 1 (MDR1) ABCB1 c.295_298delAGAT (p.
Asp75fs)
• Australian Shepherd
• Collie
• Shetland Sheepdog
• >10 other breeds
• Chinook: 7/47 (14.9%)
• Danish-Swedish Farmdog: 2/168 (1.2%)
Multifocal Retinopathy 1 (cmr1) BEST1 c.73C>T (p.Arg25*) • Australian Shepherd
• Bulldog
•Great Pyrenees
•Mastiff
• >10 other breeds
Brazilian Terrier: 25/107 (23.4%)
Multifocal Retinopathy 3 (cmr3) BEST1 c.1388delC (p.Pro463fs) Lapponian Herder Finnish Lapphund: 3/218 (1.4%)
Myotonia Congenita CLCN1 c.2665insA (p.Arg889fs) Australian Cattle Dog Border Collie: 2/29 (6.9%)
Primary Lens Luxation (PLL) ADAMTS17 c.1473+1G>A • American Hairless
Terrier
• Chinese Crested
• Jack Russell Terrier
• >20 other breeds
Danish-Swedish Farmdog: 37/168 (22.0%)
Progressive Early-Onset
Cerebellar Ataxia
SEL1L c.1972T>C (p.Ser658Pro) Finnish Hound Norrbottenspitz: 13/103 (12.6%)
Rod-Cone Dysplasia 3 (rcd3) PDE6A c.1940delA (p.Asn616fs) •Welsh Corgi Cardigan
•Welsh Corgi
Pembroke
• Chinese Crested: 1/48 (2.1%)
• Pomeranian: 1/8 (12.5%)
von Willebrand's disease, type I VWF c.7437G>A (p.Ser2479Ser) • Bernese Mountain
Dog
• Doberman
•Manchester Terrier
• >10 other breeds
• Barbet: 2/39 (5.1%)
• Brazilian Terrier: 1/107 (0.9%)
• Dutch Shepherd Dog—Longhaired: 1/16 (6.3%)
Kromfohrländer: 13/160 (8.1%)
(Continued)
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experiencing clinically excessive hemorrhage, but one of them exhibited marked bleeding fol-
lowing routine phlebotomy performed for this study. However, the mutant homozygotes had
significantly prolonged prothrombin times (PT) compared to adult littermates and laboratory
reference values (Fig 1A), and normal activated partial thromboplastin times (aPTT; data not
shown), which is indicative of FVII deficiency. The diagnosis was further confirmed by specific
FVII activity measurements on blood plasma from the same dogs (Fig 1B).
We were subsequently able to recruit one Finnish Hound homozygous for the FVII muta-
tion for this study. Its clinical history was unremarkable, but its PT was also prolonged (72 s)
compared to the reported laboratory reference values (10–20 s), indicating FVII deficiency.
Predisposition to urate urolithiasis due to the common hyperuricosuria
(HUU) mutation in Lagotto Romagnolo
Another variant known to be common across several breeds, like the Dalmatian and Black Rus-
sian Terrier, is the SLC2A9 gene mutation (c.616G>T) predisposing to HUU and uric acid cal-
culi formation [10,18,21]. We confirmed the genetic presence of this risk factor in six
Table 1. (Continued)
Disorder Gene and mutation Previously reported
breeds
Additional breed(s) with N observed carriers
von Willebrand's disease, type II VWF c.4937A>G (p.Asn1646Ser) •German Shorthaired
Pointer
•GermanWirehaired
Pointer
• Barbet: 1/39 (2.6%)
• Basenji: 1/7 (14.3%)
• Border Collie: 2/29 (6.9%)
• Chinese Crested Dog: 2/48 (4.2%)
• Danish Swedish Farmdog: 1/168 (0.6%)
• German Spitz—Medium size: 1/4 (25%)
• Lagotto Romagnolo: 6/637 (0.9%)
• Norwegian Elkhound, grey: 46/199 (23.1%)
• Old English Sheepdog: 1/55 (1.8%)
• Portuguese Water Dog: 1/5 (20%)
• Russian-European Laika: 1/9 (11.1%)
doi:10.1371/journal.pone.0161005.t001
Fig 1. Coagulation factor VII deficiency in theWelsh Springer Spaniel. (A) Prolonged prothrombin times (t(2) = 8.21, p = 0.007) but
normal partial thromboplastin times (data not shown); and (B) low plasma factor VII activity (t(3) = 9.17, p = 0.001) indicate functional factor
VII deficiency and increased bleeding tendency in Welsh Springer Spaniels homozygous for the F7 gene c.407G>Amissense variant.
(** P < 0.01).
doi:10.1371/journal.pone.0161005.g001
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additional breeds (Table 1) that consequently may be predisposed to complications caused by
uric acid crystal formation in the urinary tract. We therefore further examined uric acid con-
centrations in urine samples from four Lagotto Romagnolo dogs homozygous for the risk
allele, and found that all of them showed a marked increase (average 30-fold) in urine uric
acid/creatinine ratio (Fig 2). One of the affected Lagotti had experienced what was described as
an episode of stranguria.
Prevalent manifestations of primary lens luxation (PLL) in Danish-
Swedish Farmdogs
The ADAMTS17 gene variant (c.1473+1G>A) associated with the development of PLL (dis-
placement of the ocular lenses due to degeneration of zonular fibers) is prevalent in many
Fig 2. Hyperuricosuria in the Lagotto Romagnolo. Elevated urine uric acid/creatinine ratios (F(2,11) = 85.9, p = 1.93x10-7) in Lagotti
homozygous for the SLC2A9 gene c.616G>T variant indicate metabolic derangement and predisposition to urate stone formation.
(*** P < 0.001; n.s. = not significant)
doi:10.1371/journal.pone.0161005.g002
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terrier breeds [13,22]. Although some terrier ancestry is likely present in the Danish-Swedish
Farmdog, no active testing of the PLL mutation had been pursued prior to the panel screening
of this study. We show here that the previously reported ADAMTS17mutation is prevalent in
the breed with a 21.9% carrier frequency (Table 1). We identified five adult dogs (2.5–4.5 years
old) homozygous for the risk variant of which four were confirmed by an examining veterinar-
ian as exhibiting clinical lens luxation in at least one eye requiring surgical treatment. The
remaining homozygous dog was two and a half years old and not yet manifesting any ocular
signs, but is now being closely monitored for PLL.
Progressive early-onset cerebellar ataxia transferred between Nordic
breeds
A rapidly progressing severe generalized cerebellar ataxia with tremors, and failure to thrive
was characterized in Finnish Hound puppies [16]. Since the responsible mutation
(c.1972T>C) in the SEL1L gene was discovered, breeders have successfully used genetic screen-
ing to eradicate the lethal disorder from the breed, and affected dogs are no longer encountered
in practice. The disease variant was considered breed-specific to the Finnish Hound; yet, our
panel test found carriers from another Nordic breed, the Norrbottenspitz (also known as the
Nordic Spitz). The Finnish breed club describes the Norrbottenspitz population as being fairly
heterogeneous with open stud books. We explored the relatedness of all thirteen confirmed car-
riers using the Finnish Kennel Club registry and observed that they shared ancestry to the
same dogs registered into the breed in the 1990’s (Fig 3). We subsequently screened an addi-
tional separate 41 Norrbottenspitzes, all representing different unrelated litters, and observed
no further carriers of the mutant allele.
Importantly, a mating of two carrier dogs was observed in the registry pedigree of the Norr-
bottenspitz, and one puppy from the resulting litter had been euthanized at the age of four
months due to progressive neurological signs first observed at the age of nine weeks. The veter-
inary medical records indicated that the puppy had suffered from generalized ataxia with
hypermetria, tremor, and bilateral absence of blink reflexes. A diagnosis of cerebellar cortical
abiotrophy with enlarged cerebrospinal fluid compartment and sulci was confirmed by mag-
netic resonance imaging (MRI). No changes to the cerebrum or brainstem were detected.
Although no DNA sample was available to confirm the genotype of the euthanized puppy,
these clinical findings strikingly resemble those reported in Finnish Hounds with cerebellar
ataxia [16].
ITGA10 gene mutation causes dwarfism in Chinooks
The Chinook is a rare sled dog breed native to New England, tracing back to a male husky/mas-
tiff-type dog with the same name born in 1917. Breeders first documented chondrodysplastic
Chinooks in the 1990’s. All known cases in the breed can be traced back to a brother-sister mat-
ing producing the first known case. No conclusive information on the ancestry of these dogs
exists. Intriguingly, we present an unexpected molecular explanation for one type of dispropor-
tionate dwarfism in the Chinook breed: an ITGA10 variant (c.2083C>T) which was already
known to cause disproportionate short stature dwarfism of varying severity in the Norwegian
Elkhound and Karelian Bear Dog breeds [23]. This incidental finding by DNA panel screening
led us to cooperate with breeders aiding in the identification of at least one chondrodysplastic
Chinook dog we confirmed to be homozygous for the ITGA10 variant, and several other carri-
ers that are all related to the original cases from the 1990’s (Fig 4A). The homozygous mutant
dog has a veterinary clinician-confirmed dwarf phenotype (Fig 4B), and early-onset hip prob-
lems and osteoarthritis were also reported.
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Familial nephropathy (FN) due to a COL4A4mutation in the Welsh
Springer Spaniel
Presence of a hereditary renal condition resembling human Alport syndrome and known by
the names familial nephropathy (FN) or autosomal recessive hereditary nephropathy (ARHN)
has long been known in the English Cocker Spaniel breed [24]. Since identification of the
responsible mutation (c.115A>T) in the type IV collagen gene COL4A4, controlled breeding
and exclusions in registering offspring of known carriers have contributed to the elimination of
the condition from the gene pool of the English Cocker Spaniel breed. Through DNA panel
screening, we report here that the same mutation is also genetically present in several lines of
the Welsh Springer Spaniel breed. Incidentally, this finding was made possible by breeders set-
ting out to actively explore the prevalence of a far milder condition discovered by us in the
breed, FVII deficiency described above. By the analysis of the pedigree registry of the Finnish
Fig 3. Inheritance of cerebellar ataxia in a pedigree of Norrbottenspitzes. All Norrbottenspitzes identified as carrying the Finnish Hound ataxia
mutation (SEL1L c.1972T>C) can be traced back to the oldest obligate carrier dog (marked with an arrow symbol). Three dogs of unconfirmed
background (squared on gray background) registered into the breed represent potential events of introduction of the mutation into the
Norrbottenspitz populaation. A puppy (squared on white background) euthanized due to neurological symptoms matching the expected disease
phenotype was born from a mating between two carrier dogs. Gender symbols of dogs with unconfirmed genotypes are shaded gray.
doi:10.1371/journal.pone.0161005.g003
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Kennel Club, we confirmed that a mating between two carrier dogs had taken place, producing
a puppy that had been euthanized at the age of 10 months due to chronic renal insufficiency
(classified as International Renal Interest Society stage 3 of 4).
Fig 4. Chondrodysplasia in the Chinook. (A) Inheritance of chondrodysplasia in a pedigree of Chinooks. All carriers of the responsible
variant (ITGA10 c.2083C>T), and a genetically affected dog (squared) confirmed to have a dwarf phenotype are related to the first
dwarves documented in the 1990’s as a result of a brother-sister mating (marked with an x). The mutation was likely propagated in the
population through the sire of that mating (marked with an arrow), who was further bred to several other females. Gender symbols of
dogs with unconfirmed genotypes are shaded gray. (B) A Chinook displaying the dwarfism phenotype (left; and squared in the pedigree)
with crooked and shortened legs is shown in comparison to a normal Chinook (right).
doi:10.1371/journal.pone.0161005.g004
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Canine multifocal retinopathy (cmr)- associated variants in the Brazilian
Terrier and Finnish Lapphund
Different mutations in the BEST1 gene are known causes of canine multifocal retinopathy
(cmr) in Mastiff-related breeds, Coton de Tulear, and Lapponian Herder [15,25]. In this study,
we report the first encounter of the cmr type 1 (cmr1) variant (BEST1 c.73C>T) in a terrier
breed, the Brazilian Terrier. Moreover, a few carriers of the cmr3 variant (BEST1 c.1388delC)
originally found in Lapponian Herder were also found in the closely related Finnish Lapphund
breed.
We further explored the prevalence of cmr1 in the Brazilian Terrier by separate genotyping
in a randomly selected sample population of 233 dogs. Five mutant allele homozygotes (2.1%)
and 52 carriers (22.3%) were identified, closely corresponding to the carrier frequency observed
during the initial panel screening (23.4%). Of the five mutant homozygotes, three had previ-
ously undergone ophthalmology examinations or were re-examined for this study, and two
were not available for clinical evaluation. We did not observe any apparent retinal changes,
such as multifocal areas of retinal elevations with subretinal accumulation of serous pink-tan
fluid, in the examined Brazilian Terriers homozygous for the cmr1 variant (Table 2).
During sequencing validation of the cmr1 nonsense variant (BEST1 c.73C>T; p.Arg25), we
incidentally also discovered another synonymous (silent) and therefore likely benign base sub-
stitution at the same position (c.73C>A [p.Arg25Arg]) in the several breeds (Cirneco dell’Etna,
Parson Russell Terrier, Rhodesian Ridgeback, Schipperke, and St Bernard).
Other disease variant findings in additional breeds
Beyond the findings pursued in more detail above, we found other known mutations in addi-
tional breeds as well (Table 1). Further studies will be crucial in addressing if these known vari-
ants cause a similar clinical phenotype in the additional breeds discovered. The well-known
MDR1 (multi-drug resistance 1) mutation c.295_298delAGAT [26] was observed in two previ-
ously undocumented breeds, the Chinook and Danish-Swedish Farmdog. Notably, the vWF
gene variant c.4937A>G previously associated with von Willebrand’s disease (vWD) type II
[27] was present in many more breeds than currently acknowledged. A variant identified as a
risk factor for craniomandibular osteopathy (CMO) in terriers [28] was also found at low fre-
quency in other breeds. Based on the genetic findings of this study, examination of the rod-
cone dysplasia 3 (rcd3; [29]) variant PDE6A c.1940delA as a factor explaining retinal signs in
the Chinese Crested and Pomeranian breeds is warranted. The discovery of a variant (CLCN1
c.2665insA) known to cause myotonia congenita in the Australian Cattle Dog [30] in another
breed popular in Australia, the Border Collie, calls for an investigation of whether its presence
is limited to a single line of dogs or is more widespread in the breed. Acatalasemia, the defi-
ciency of catalase enzyme activity associated with a CAT gene variant (c.979G>A), was
Table 2. Summary of ophtalmological examinations in the Brazilian Terrier.
Dog Year of
birth
Sex Year of ophtalmology examination
(s)
Findings
Dog
1
2006 Female 2008, 2014 No abnormalities
Dog
2
2007 Female 2011, 2013 No abnormalities
Dog
3
2004 Female 2008, 2014, 2015 • 2008: Distichiasis and suspected vitreous degeneration
• 2014: Cortical and posterior polar cataract and vitreous degeneration
• 2015: No abnormalities in the ocular fundus detected by Optical Coherence
Tomography
doi:10.1371/journal.pone.0161005.t002
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originally characterized in research colonies of Beagles [31,32]. In this study, we observed the
variant also in a carrier American Foxhound. To our knowledge, presence and manifestation of
acatalasemia due to the aforementioned CAT variant has not been previously documented in
the pet Beagle population. We therefore note that we identified pet Beagle carriers, and a ten-
month-old mutant homozygous Beagle through panel screening. During this investigation, the
genetically affected Beagle developed gangrene of the oral cavity leading to the removal of three
teeth at the age of eighteen months, which could be a manifestation of acatalasemia [31].
Discussion
Through the application of a novel DNA panel screening test for nearly 100 disorders on a
cohort of almost 7000 dogs, we found a high overall frequency of mutation carriers (17.8%)
while discovering a sixth (15/93) of the tested disease-causing variants in additional breeds.
Our findings demonstrate the power of multiplex screening as an efficient genetic testing and
discovery platform for research, diagnostics and breeding. Our pioneering examples further
highlight several general implications related to the approach.
First, panel screening yields new insights into the prevalence and significance of genetic risk
variants across breeds. We show that several mutations are more widespread across breeds
than reported in original studies with a limited sample size or breed focus, and they often–but
not always–cause the same condition in the additional breeds. Therefore, there is a need for
careful follow up of any unexpected discoveries. We encourage publication of such findings
made during routine DNA testing, but preferably in combination with appropriate clinical evi-
dence supporting genetic counseling and demonstrating relevance of the discovery for breeding
selections and veterinary care. Within the scope of this study, we provide strong evidence sup-
porting the clinical relevance of six known inherited conditions in additional breeds, while set-
ting the groundwork for several future investigations.
Second, panel screening is particularly efficient when examining the breed distribution of
widespread mutations likely ancient in origin. Accordingly, we present several discoveries on
putative ancient variants in additional breeds (e.g., FVII, HUU, PLL, MDR1, and vWD). These
disorders also represent recessively inherited conditions with clinical signs that may only be
evident upon exposure to a trigger, or not primarily attributed to a specific genetic defect. One
could expect such ancient variants to be readily retained in the population. We hypothesize
that many more breeds harboring known ancient (and other) mutations will be discovered dur-
ing future DNA screening as the numbers of tested disease variants, breeds, and dogs of each
breed increase.
Third, open-minded panel screening even when no gene tests are known to be relevant for a
breed a priorimay lead to surprising discoveries that are relevant for breed health. This is
exemplified by our discoveries of “Finnish Hound” cerebellar ataxia in the Norrbottenspitz,
and “Norwegian Elkhound” dwarfism in the Chinook. Such findings also illustrate how inad-
vertent more recent transfer of mutations between breeds breaks perceived patterns of breed-
specificity of genetic disease variants. Pedigree databases alone are unlikely to account fully for
the molecular genetic disease heritage historically introduced into a breed. Several breed clubs
are engaged in cross-breeding projects to expand the gene pool and improve the health of their
breed. While these efforts are commendable, we postulate that they may further benefit from
comprehensive genetic screening to ensure that known disease variants are not inadvertently
introduced and subsequently enriched in the breed.
More specifically, we established presence of several disorders in additional breeds. Based
on the combination of molecular, clinicopathologic and pedigree evidence presented herein,
breeders and veterinarians should be aware of these conditions in their breeds and patients,
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respectively. FVII deficiency should be considered in Welsh Springer Spaniels and Finnish
Hounds, which could exhibit bleeding tendency upon trauma or surgery. Lack of spontaneous
bleeding signs in homozygous dogs highlights the mild nature of this coagulopathy, but raises
concerns when combined with additional impairments of hemostasis such as hepatic disease,
poisoning, and certain drug therapy. The awareness of HUU in additional breeds such as the
Lagotto Romagnolo is helpful in guiding veterinarians to appropriate dietary selection, drug
therapy and regular follow up for dogs at risk. Similarly, our discovery of PLL in the Danish-
Swedish Farmdog has already proven crucial for proper monitoring and care of this potentially
painful and severe ocular condition in dogs at risk. Swift availability of a molecular explanation
for this phenotype and a validated DNA test is a relief to breeders. Based on documenting the
shared ancestry of all identified carriers, we find it likely that the ataxia mutation originally
found in the Finnish Hound was introduced into the Norrbottenspitz breed by registration
uptake of dogs of unconfirmed heritage. Our fortunate discovery of the variant transfer has
since led to active screening of the breed, and thereby prevention of the birth of further affected
puppies while keeping healthy carriers in the gene pool. We further provide a molecular genetic
cause for one form of dwarfism segregating in the Chinook breed, simultaneously providing an
intriguing ancestral link to the Norwegian Elkhound breed.
Finally, we also established the presence of a variant known to cause FN in the English
Cocker Spaniel in Welsh Springer Spaniels. Homozygosity for this variant provides a plausible
retrospective explanation for renal failure in at least one puppy. Although the genotype of the
puppy could not be confirmed, protein truncation by the COL4A4mutation, likely causing
inability to combine with other collagen chains [24], makes it plausible that the pathological
consequences are similar as in the original discovery breed. Truncation of the P-glycoprotein
drug transporter (ABCB1 gene) due to the well-known MDR1 mutation [26] is likely to pose a
risk for severe neurotoxic side effects in any dog being administered drugs normally trans-
ported by the protein. We therefore alert veterinary clinicians to the presence of MDR1 also in
the Chinook and Danish-Swedish Farmdog.
Our examination of cmr1 eye disease serves as an example of the practical importance of
two hallmarks of high fidelity panel screening: 1) confirmation of any novel finding with a sec-
ond genetic technology; and 2) clinical evaluation of the relevance of the genetic finding for the
breed before breeding advice is given. First, sequencing confirmation of cmr1 findings revealed
the triallelic nature of position c.73C in the BEST1 gene. While some breeds carry the actual
c.73C>T mutation, others harbor a likely harmless synonymous c.73C>A change. Awareness
of this triallelic site in routine DNA testing is important, as it may lead to erroneous interpreta-
tions with some genotyping technologies, particularly if applied to mixed breed dogs. It
remains to be determined whether all three alleles at this specific position are present in some
breeds. Second, the clinical validation of a variant in an additional breed may end in lack of evi-
dence for a pathological phenotype. Based on the evidence at hand, cmr1 is unlikely to be a pri-
mary health concern in Brazilian Terriers warranting DNA testing, and carriers should not be
eliminated from breeding programs. In general, the lack of a disease phenotype in additional
breeds may necessitate re-evaluation of the initially reported disease-association in the original
breed.
Taken together, our findings illustrate the broad potential of panel screening to: 1) advance
breed health and genetics research through information on the breed distribution of mutations;
2) further pet care through preventive medicine on conditions with actionable treatment (e.g.,
awareness of bleeding propensity before surgery, guidance of dietary selection and monitoring
in HUU, prophylactic medication and surgery in PLL, selection of safe medication based on
pharmacogenetics such asMDR1 genotype); 3) support veterinary molecular diagnostics (e.g.,
by provision of a plausible genetic explanation for clinical signs related to nephropathy in the
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Welsh Springer Spaniel); 4) prevent an emerging but still hidden severe breed health issue
from spreading (e.g., ataxia in the Norrbottenspitz); and 5) effectively explain the molecular
background of a breed health-related phenotype not being the primary research focus of any
research group (e.g., dwarfism in the Chinook).
This is the first large scale report of DNA panel screening across purebred dogs to date, and
as such we note that the investigation should be expanded to include additional disease variants
and breeds in the future. Moreover, our study sample was biased towards specific breeds with
active DNA testing routines and interests. We also expect some of the disease carrier frequen-
cies reported herein to be higher than would be observed in randomly selected samples of the
respective breeds due to bias generated by testing of relatives of carrier and affected dogs. The
vast majority of the studied dogs represented breeds with at least one known breed-relevant
test among the screened variants, and thus at least a minimum return from the testing. We
believe that comprehensive DNA testing also on the remaining ~1/3 of dogs (including breeds
with health concerns lacking molecular explanations, breeds lacking an active culture of DNA
testing, and more rare understudied breeds) is best justified by the practical examples of novel
findings in more than 30 breeds recounted in this report. The Danish-Swedish Farmdog also
provides an extreme example of a breed entering the study with no known relevant DNA tests,
and leaving it with four potential new conditions to consider in veterinary care and breeding.
Although multiplex screening is a powerful diagnostics and research tool from the perspective
of a veterinary clinician or researcher, a breeder or dog owner should not be blinded by the num-
ber of tests performed. Rather, one should think of panel screening as an accurate, convenient
and cost-efficient method to obtain as many breed-relevant test results as possible with one anal-
ysis while simultaneously contributing to breed health- and canine genetics research in a novel
way. Genetic counseling based on panel screening results should make it clear that the purpose of
the test is not to provide a universal health certificate or give a verdict on which dog can be bred.
The testing simply provides information on the specific mutations being assayed, leaving other
unknown genetic and environmental health risks unexplored. Conveying these messages appro-
priately is particularly important when screening dogs with no prior known breed-relevant tests.
Taken together, despite the need for comprehensive tools to manage the growing number of
known disease mutations in breeding, the best long term solution that prevents enrichment and
emergence of recessive disorders is informed breeding selections regarding known deleterious
variants in combination with maintenance of genetic diversity guided by pedigree-based statistics
and modern molecular genetic measurements, as previously discussed [33].
Conclusions
We conclude that DNA multiplex screening for canine hereditary disorders represents a reli-
able and powerful discovery and utility tool for applications in veterinary diagnostics, genetic
research, and sustainable breeding. We demonstrate that several disease-causing mutations are
likely affecting and more widespread than recognized during original discovery studies due to
shared breed ancestry or more recent cross-breeding. Careful genetic and clinicopathological
verification to establish genotype-phenotype correlations should be part of a high quality panel
screening service. Importantly, comprehensive disease screening needs to be carried out,
interpreted and reported responsibly, maintaining close ties to high quality genetics research,
caring veterinarians, breeders, breed health committees and kennel clubs. Panel screening, as
any single DNA test, should only be viewed as one part of a breeding decision and strategy.
Holistic approaches working towards overall breeding goals that are beneficial not only for the
immediate health of the offspring, but also for the sustainability of the breed as a whole, are
recommended.
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